GET DAILY SIGNALSSeaStar Medical (ICU): Examining the SCD Platform and Its Role in Critical Care
Key Takeaways
- ICU is the Nasdaq ticker for SeaStar Medical Holding Corporation, a commercial-stage medical technology company based in Denver, Colorado.
- The company develops extracorporeal therapies built around its Selective Cytopheretic Device (SCD), which targets the hyperinflammation that can damage vital organs in critically ill patients.
- Its first FDA-authorized product, QUELIMMUNE, treats acute kidney injury (AKI) caused by sepsis in pediatric patients, while NEUTRALIZE-AKI is being studied for adult AKI.
- SeaStar Medical operates a single device segment, generates relatively modest revenue, and remains in a clinical and commercial build-out phase, with a very small workforce and micro-cap financial profile.
- Investors follow ICU primarily for its pipeline potential, regulatory milestones, and the addressable market in critical-care inflammation, rather than for current profitability.
Introduction
SeaStar Medical Holding Corporation focuses on mitigating the damaging effects of hyperinflammation on vital organs. This overreaction of the immune system can lead to a cytokine storm that harms the kidneys and other organs in patients who are severely ill. The company’s core technology, the Selective Cytopheretic Device (SCD), works to neutralize overactive immune cells. Given its emphasis on conditions like sepsis-associated acute kidney injury, the firm attracts interest from those following medical devices, renal care, and the wider biotechnology space.
Company Overview and Business Model
Founded in 2007 and headquartered in Denver, Colorado, SeaStar Medical develops medical technology rather than operating as a broad manufacturer. It reports results under a single segment centered on its device operations. The approach involves designing therapies, obtaining regulatory approvals, and bringing extracorporeal treatments to market that address the inflammatory processes behind organ damage.
At the center is the Selective Cytopheretic Device (SCD), a platform intended to modify disease by calming overactive immune cells and interrupting the cytokine storm. From this base, the company has created specific therapies:
- QUELIMMUNE — an SCD-based option authorized for pediatric patients experiencing acute kidney injury due to sepsis or septic conditions that require kidney replacement therapy.
- NEUTRALIZE-AKI — an SCD therapy under evaluation in clinical studies for adult patients with AKI.
Additional applications have been explored in areas such as cardiorenal syndrome and hepatorenal syndrome, supported by multiple FDA Breakthrough Device Designations. This structure means current financial results reflect ongoing investment in research and launch activities more than steady revenue from diversified sources.
Why Investors Follow ICU
Attention centers on the clinical and regulatory progress of the SCD platform. Several elements contribute to ongoing interest:
- Unmet medical need: Sepsis-associated acute kidney injury represents a serious condition with few existing treatments, pointing to a potentially sizable market in critical care.
- Regulatory milestones: Advances with FDA authorizations, trial enrollment, and post-approval requirements shape the path to commercialization.
- Platform potential: By targeting the underlying inflammatory process rather than one specific disease, the technology could apply to multiple organ-related conditions.
- Commercial ramp-up: As a commercial-stage company, growth in QUELIMMUNE adoption and future launches serve as important indicators for investors.
From what I see, the financial profile remains that of an early-stage firm, with modest revenue, ongoing losses, and a limited commercial presence while adoption expands.
Risks and Important Considerations
Like many small-cap medical technology and biotechnology companies, ICU involves notable risks that deserve careful review:
- Clinical and regulatory risk: Products such as NEUTRALIZE-AKI still need successful trial outcomes and clearances, which are never assured.
- Commercial execution risk: Building adoption for a specialized therapy in hospital settings can prove slow and resource-intensive.
- Financial profile: Operations feature a small team, limited revenue, and repeated net losses that may lead to further capital raises and potential dilution.
- Concentration risk: Reliance on a single platform and narrow set of indications heightens exposure to setbacks in any one area.
- Market and liquidity risk: As a micro-cap stock, ICU can show greater volatility and lower trading liquidity than larger healthcare peers.
Conclusion
SeaStar Medical Holding Corporation holds a focused position in medical technology through its Selective Cytopheretic Device platform aimed at hyperinflammation and organ injury. QUELIMMUNE addresses pediatric sepsis-associated acute kidney injury, while the broader pipeline suggests additional possibilities. For investors, ICU remains a development-oriented healthcare story where clinical progress, regulatory outcomes, and commercial uptake will likely drive the longer-term path.
Using Tickeron’s AI Screener in My Research
I also checked this using Tickeron’s AI Screener to compare ICU with other names in the medical technology space. The tool lets me apply technical indicators, fundamentals, volatility measures, and AI signals to narrow down ideas quickly. It supports a more structured way to review opportunities that fit specific strategies without replacing broader due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ICU in -7.84% downward trend, sliding for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ICU declined for three days, in 288 of 318 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICU as a result. In 79 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for ICU turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
ICU moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ICU crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
The 50-day moving average for ICU moved below the 200-day moving average on October 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for ICU entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ICU's RSI Oscillator exited the oversold zone, 31 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICU advanced for three days, in 150 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ICU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.929) is normal, around the industry mean (3.498). P/E Ratio (-0.995) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.468) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. ICU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement